有机阴离子转运体1/3对银杏内酯及白果内酯药代动力学和肾脏排泄的影响
该研究评估OAT1/3在银杏内酯A、B、C及白果内酯药代动力学和肾脏排泄中的作用。体外细胞实验显示四者为OAT1/3低亲和力底物;大鼠联合丙磺舒后,银杏内酯A、B及白果内酯AUC显著增加、清除率降低,肾脏蓄积和尿排泄减少。结论提示OAT1/3介导其肾脏排泄,OAT1/3抑制剂显著影响其药代动力学。
要点
- 银杏内酯A、B、C及白果内酯为OAT1/3低亲和力底物。
- OAT1/3抑制剂丙磺舒可显著升高银杏内酯A、B及白果内酯的血药浓度。
- 临床合用OAT1/3抑制剂时需关注银杏萜类内酯的暴露变化。
核心结论
- 银杏内酯A、B及白果内酯通过肾脏OAT1/3介导的转运排泄,OAT1/3抑制剂显著影响其药代动力学。
研究设计与样本
- 体外用过表达OAT1或OAT3的MDCK和HEK293细胞研究摄取。
- 大鼠体内研究药代动力学、肾脏蓄积和尿排泄,验证体外结果。
主要发现
- 银杏内酯A、B、C及白果内酯是OAT1/3的低亲和力底物。
- 丙磺舒联用后大鼠血浆银杏内酯A、B及白果内酯浓度显著升高。
- 丙磺舒组AUC显著增加:银杏内酯A 893.48 vs. 1123.85、银杏内酯B 314.91 vs. 505.74、白果内酯2724.97 vs. 3096.40 μg/L*h。
- 丙磺舒组这些化合物的清除率显著降低。
- 丙磺舒组肾脏蓄积分别降低1.8、2.4和1.5倍,累积尿回收率进一步降低。
临床怎么用
- 使用银杏叶提取物制剂时,应评估患者是否合用OAT1/3抑制剂(如丙磺舒)。
- 合用OAT1/3抑制剂可能增加银杏内酯A、B及白果内酯的体内暴露,需关注安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The major terpene lactones of ginkgo biloba extract (GBE) include ginkgolide A, B, C and bilobalide are used for the protection of cardiovascular, cerebrovascular and neurodegenerative diseases. Terpene lactones are orally bioavailable and predominantly eliminated via the renal pathway. However, information on the transporters involved in the pharmacokinetics (PK) and renal excretion of terpene lactones is limited. AIM OF THE STUDY: The objective of this study is to assess the role of OAT1/3 which are important transporters in the human kidney in the PK and renal excretion ginkgolide A, B, C and bilobalide. MATERIALS AND METHODS: Uptake of ginkgolide A, B, C and bilobalide in Madin-Darby Canine Kidney (MDCK) and human embryonic kidney 293 (HEK293) cells overexpressing OAT1 or OAT3, respectively were studied. To verify the result from in vitro cell models, the studies on PK, kidney accumulation and urinary excretion of ginkgolide A, B, C and bilobalide were carried out in rats. RESULTS: The result showed that ginkgolide A, B, C and bilobalide are low-affinity substrates of OAT1/3. Following co-administration with probenecid, a typical inhibitor of OAT1/3, the rat plasma concentrations of ginkgolide A, B, C and bilobalide increased significantly. AUC showed a significant increase in the probenecid-treated rats compared to control rats (893.48 vs. 1123.85, 314.91 vs. 505.74, and 2724.97 vs. 3096.40 μg/L*h for ginkgolide A, B and bilobalide, respectively), while the clearance of these compounds significantly decreased. The accumulation of ginkgolide A, B and bilobalide in the kidney of the probenecid-treated rats was reduced by 1.8, 2.4, and 1.5-fold, respectively; further reducing the cumulative urinary recovery of these compounds. CONCLUSION: The findings indicated that ginkgolide A, B and bilobalide are excreted via OAT1/3-mediated transport in the kidney and OAT1/3 inhibitor significantly influence the PK ginkgolides and bilobalide.
引用
- Yaro P, Nie J, Xu M, et al. Influence of organic anion transporter 1/3 on the pharmacokinetics and renal excretion of ginkgolides and bilobalide. J Ethnopharmacol. 2019. PMID: 31325605. doi:10.1016/j.jep.2019.112098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。